SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin rises on getting approval for Sevelamer Carbonate Tablets

25 Jan 2021 Evaluate

Lupin is currently trading at Rs. 1085.95, up by 6.40 points or 0.59% from its previous closing of Rs. 1079.55 on the BSE.

The scrip opened at Rs. 1085.00 and has touched a high and low of Rs. 1103.65 and Rs. 1049.95 respectively. So far 233596 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1121.85 on 18-Sep-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 1103.65 and Rs. 1034.55 respectively. The current market cap of the company is Rs. 49333.24 crore.

The promoters holding in the company stood at 46.88%, while Institutions and Non-Institutions held 40.05% and 12.79% respectively.

Lupin has received approval for its Sevelamer Carbonate Tablets, 800 mg, from the United States Food and Drug Administration, to market a generic equivalent of Renvela Tablets, 800 mg, of Genzyme Corporation.

Sevelamer Carbonate Tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

 

Lupin Share Price

2332.55 8.30 (0.36%)
20-Apr-2026 09:26 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1677.45
Dr. Reddys Lab 1234.80
Cipla 1241.25
Zydus Lifesciences 948.10
Lupin 2332.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×